Danaher Corp
DHRQ1 2025(DHR Q4 FY2024)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$805.4M
AI Revenue (Q)
$174.8M
Total Revenue (Q)
$17.5B
Source: SEC EDGAR 10-K Filing
View 10-K on SEC.govAnalysis
Q4 FY2024 (derived from full-year 10-K ended December 31, 2024). Full-year sales $23,875M; nine-month sales $17,337M; Q4 = $6,538M. Segments (FY): Biotechnology $6,759M, Life Sciences $7,329M, Diagnostics $9,787M. The 2024 10-K repeats the AI risk factor from 2023 but provides no AI revenue disclosures. New enhanced segment disclosures (ASU 2023-07) break out depreciation, amortization, impairments, and other segment expenses, but still no AI line item. Life Sciences segment took $265M in total impairments (including genomics). Conservative 1% for embedded instrument algorithms. Math: ~$65M estimated / $6,538M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Total Sales $23,875 [year ended December 31, 2024]
10-K FY2024, Note 6 Segment Information
Biotechnology $6,759; Life Sciences $7,329; Diagnostics $9,787 [full year 2024]
10-K FY2024, Note 6 Segment Information
Uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products may result in harm to our business and reputation
10-K FY2024, Item 1A Risk Factors summary
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Biotechnology consumables/bioprocessingLife Sciences instrumentsDiagnostics instruments
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix